Results 231 to 240 of about 345,366 (342)

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao   +6 more
wiley   +1 more source

Genetic variants underlying precancerous conditions of hepatocellular carcinoma

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 80% of cases worldwide. While chronic hepatitis B and C infections remain primary risk factors, emerging evidence highlights the increasing contributions of metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease
Jonathan Jaime G. Guerrero   +7 more
wiley   +1 more source

Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis

open access: yesiMetaMed, EarlyView.
Flow chart of malignant mesothelioma of the tunica vaginalis testis (MMTVT) diagnosis and treatment process. ABSTRACT Malignant mesothelioma of the tunica vaginalis testis (MMTVT) is a rare malignancy originating from mesothelial cells of the testicular tunica vaginalis.
Yiqing Cai   +106 more
wiley   +1 more source

Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease

open access: yesiMetaOmics, EarlyView.
This narrative review uniquely addresses how gut microbiota‐derived metabolites mediate overlapping pathologies of insulin resistance, neuroinflammation, and amyloidogenesis in type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), proposing a framework for dual therapeutic targeting.
Guangyi Xu   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy